Naobios — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Naobios is a specialized CDMO with over 15 years of expertise in developing and manufacturing virus-based biologics for preclinical and clinical stages. The company offers end-to-end services from upstream and downstream process development to GMP manufacturing and quality control, with particular strengths in handling live and inactivated viruses, oncolytic viruses, and viral challenge agents. As a subsidiary of Clean Biologics, it leverages group synergies to serve global sponsors in the vaccine and advanced therapy sectors, supported by facilities capable of handling high-containment pathogens.

Infectious DiseaseOncology

Technology Platform

GMP biomanufacturing platform for virus-based products, including expertise in multiple cell lines (Vero, MRC-5, BHK-21, EB66®, CAP, AGE1®CR), microcarrier and fixed-bed bioreactor systems (up to 200L STR/200m² iCELLis), and full bioprocess development (USP/DSP). Capabilities include BSL2 and BSL3 containment manufacturing, aseptic fill-finish, and analytical development.

Opportunities

The growing demand for CDMO services in complex viral modalities like oncolytic viruses and viral vectors presents a significant opportunity.

Naobios's unique BSL3 manufacturing capability positions it to win contracts for high-containment pathogens and challenge agents, a niche but expanding market.

Strategic partnerships, like the one with SGS for RSV, can open doors to large-scale vaccine development programs.

Risk Factors

Revenue is dependent on a limited number of client projects, creating vulnerability to pipeline delays or cancellations.

The company operates in a highly competitive CDMO landscape against larger players with greater resources.

Maintaining stringent GMP and biosafety compliance in BSL3 operations carries inherent regulatory and operational risks.

Competitive Landscape

Naobios competes with other specialized viral CDMOs (e.g., Oxford Biomedica, Batavia Biosciences) and the viral vector/vaccine manufacturing divisions of large, diversified CDMOs (e.g., Lonza, Catalent). Its differentiation lies in its specific focus on live/inactivated viruses, BSL3 containment, and integrated service within the Clean Biologics group. Competition is based on technical expertise, capacity, speed, and cost.

More companies in Biologics / Biosimilars →More companies in France →